Several observational studies have specifically examined infections such as pneumonia and sepsis, which have not been comprehensively evaluated in RCTs, and some suggest that SGLT2 inhibitors may reduce the risk of these infections compared to other glucose-lowering medications [15, 16]. The gene discussed is SLC5A2; the disease is infection.